CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.019
https://www.valueinhealthjournal.com/article/S1098-3015(21)00236-9/fulltext
Title :
CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00236-9&doi=10.1016/j.jval.2021.04.019
First page :
Section Title :
Open access? :
No
Section Order :
10728